ProBio
@ProBioTrial
Followers
140
Following
28
Media
49
Statuses
84
ProBio is an outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven trial in patients with metastatic prostate cancer
Joined January 2019
🔥📢 The first results from the @ProBioTrial have been published in @NatureMedicine 🚀🌟. ARPIs outperform taxanes in metastatic #ProstateCancer: an outcome-adaptive randomized platform trial 🌟 [1/10].
1
20
32
This research was made possible by the support of:.@ALFmedicin , @Cancerfonden , Radiumhemmet Research Funds, @Prostatacancerforbundet, @Vetenskapsradet , Krebsliga beider Basel, & @KomOpTegenKanker. THANK YOU! 🙏 . [8/8]. #CancerResearchMatters.
0
0
0
What’s next?. 🏥 @ProBioTrial will explore treatment de-escalation for low-ctDNA patients. 🔬 Future trials should integrate ctDNA fraction 🩸🧬 as a stratification tool. 👨⚕️ ctDNA may guide guide #PrecisionMedicine in all #ProstateCancer patients?. [7/8].
1
0
2
Why does this matter?. 🧬 Patients with undetectable ctDNA may need less intensive treatment & monitoring. Towards a ctDNA-driven de-escalation strategy? . ⚠️ Patients with high ctDNA in their🩸 may benefit from earlier aggressive treatment. [6/8].
1
1
1
🏅Secondary result:. We found a linear relationship between ctDNA 🩸 levels and outcome: . 📉 Every 10% increase in ctDNA fraction led to a 9% decrease in the observed survival time. 💡 The more ctDNA in🩸, the worse the outcome!. #PrecisionMedicine . [5/8]
1
4
7
🏅Key result:. 🧬🩸 Compared to those with detectable ctDNA, men with undetectable ctDNA had . ➡️a 60% longer time before treatment stopped working (time to no longer clinically benefiting, NLCB) . ➡️a 51% longer overall survival (OS) 📉. #CancerBiomarkers. [4/8]
1
1
2
We analyzed 220 men with metastatic castration-resistant #ProstateCancer from the @ProBioTrial . ➡️139 had detectable ctDNA.➡️81 had undetectable ctDNA . What did we find? Patients with undetectable ctDNA lived much longer! 🔬📊. #PrecisionOncology. [3/8]
1
0
2
🧬 ctDNA is tumor-derived DNA found in the bloodstream 🩸. 📢Our study shows that men with undetectable ctDNA in their #LiquidBiopsy have significantly better survival outcomes. 🔍 Full manuscript available on @EurUrolOncol: . [2/8].
1
1
1
🚨 New Study Alert! 🚨. What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC. A thread 🧵👇 #CancerResearch #ProstateCancer. [1/8]
1
6
9
RT @urotoday: AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #….
0
5
0
RT @urotoday: AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #….
0
6
0
RT @urotoday: AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the P….
0
11
0
RT @piet_ost: Don’t forget the @ProBioTrial is an investigator-initiated trial! Crazy level of commitment of everyone involved.
0
6
0
Meet the @ProBioTrial consortium: healthcare professionals from 🇸🇪🇧🇪🇳🇴🇨🇭specialised in the treatment of men with metastatic #ProstateCancer . They made the 🥈#ProBioTrial International Investigator’s Meeting a success 🙏 . Presentations soon available on
0
4
11
Final session of the day during the #ProBioTrial investigator meeting! . 📢Tour de force from @okelidokeli .🏥🧪 the path towards getting the @ProBioTrial test into clinical routine diagnostics 🩸🧬
0
0
5
Next, the #ProBioTrial team tackles the new features protocol v6.0 will have:.1) Expansion of the #ProstateCancer patient population.2) A new treatment arm for ctDNA-undetectable mHSPC.3) Towards the removal of the SOC control arm in ProBio-mHSPC
1
2
7
Day 2 starts with a presentation on survival outcomes in ctDNA-negative patients. 🔍 This research is key to better understanding how we can improve treatment outcomes in #ProstateCancer. 💡Thanks to @AlessioCrippa for leading this critical session.
1
2
5
The #ProBioTrial also listened to the voices from the patient organisations from 🇸🇪 🇧🇪 🇳🇴 They concluded that #ProstateCancer care is evolving, and today’s research could offer new hope for patients. #CancerTherapy
1
1
5
Anna Kristensen discusses the cumbersome results for Carboplatin in the treatment for mCRPC. Followed by Brieuc Sautois giving crucial insights for the future use of #PSMAPET in the evaluation of metastatic #ProstateCancer
1
1
4
Groundbreaking scientific results on ARPi vs Taxanes in metastatic castration-resistant #ProstateCancer and quality of life studies take center stage. 🔬 Thanks to @BramDL and @ReneeBultijnck for their expert insights! #mCRPC #Oncology
1
2
4
Prof. Henrik Grönberg opening the 2nd #ProBioTrial International Investigators Meeting in Stockholm! 🌍. Healthcare professionals from 🇸🇪 🇧🇪 🇳🇴 🇨🇭 are coming together to push the boundaries of #ProstateCancer cancer research and treatment. Let’s make an impact! 💪
1
4
10